Jennifer L. Taubert - 13 Feb 2023 Form 4 Insider Report for JOHNSON & JOHNSON (JNJ)

Role
EVP, WW Chair, Pharmaceuticals
Signature
Raavi K. Deol, as attorney-in-fact for Jennifer L. Taubert
Issuer symbol
JNJ
Transactions as of
13 Feb 2023
Net transactions value
-$1,712,284
Form type
4
Filing time
15 Feb 2023, 18:25:12 UTC
Previous filing
14 Feb 2023
Next filing
04 Apr 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction JNJ Common Stock Award $0 +21,422 +17% $0.000000 150,159 13 Feb 2023 Direct F1
transaction JNJ Common Stock Tax liability $1,712,284 -10,569 -7% $162.01 139,590 13 Feb 2023 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction JNJ Employee Stock Options (Right to Buy) Award $0 +64,634 $0.000000 64,634 13 Feb 2023 Common Stock 64,634 $162.75 Direct F2
transaction JNJ Restricted Share Units Award $0 +3,906 $0.000000 3,906 13 Feb 2023 Common Stock 3,906 Direct F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents Common Stock received upon the satisfaction of performance and time-based criteria for Performance Share Units awarded under Issuer's Long-Term Incentive Plan on February 10, 2020.
F2 Awarded under Issuer's Long-Term Incentive Plan. The Stock Option Award vests in three equal annual installments beginning on the first anniversary of the grant date.
F3 Awarded under Issuer's Long-Term Incentive Plan. Each Restricted Share Unit represents a contingent right to acquire one share of Common Stock.
F4 The Restricted Share Units vest in three equal annual installments beginning on the first anniversary of the grant date.